Lupin unveils generic equivalent of Perforomist Inhalation Solution in US

Published On 2022-11-29 06:30 GMT | Update On 2023-10-07 11:09 GMT

Mumbai: Global pharma major Lupin Limited today announced the launch of Formoterol Fumarate Inhalation Solution, 20 mcg/2 mL per Unit-Dose Vial in United States.

The product is a generic equivalent of Perforomist Inhalation Solution, 20 mcg/2 mL, of Mylan Specialty, L.P.

PERFOROMIST Inhalation Solution is a long-acting beta2-adrenergic agonist (beta2-agonist) indicated for:

 Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Formoterol Fumarate Inhalation Solution (RLD Perforomist) had estimated annual sales of USD 268 million in the U.S. (IQVIA MAT September 2022).

Medical Dialogues team had earlier reported that Lupin Human Welfare and Research Foundation (LHWRF), the Corporate Social Responsibility (CSR) arm of Lupin Limited, had signed a Memorandum of Understanding (MoU) with the Government of Rajasthan to address the prevalence of Cardiovascular Disease (CVD) and Chronic Obstructive Pulmonary Disease (COPD) in the Alwar district of Rajasthan.

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle-East regions.

The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. The company invested 8.7% of its revenue in research and development in FY22.

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Lupin unveils generic equivalent of Perforomist Inhalation Solution in US

Similar News

Stryker expands RnD presence in India, opens new facility in Bengaluru

CDSCO Cancels Registration Certificate of G3 Medical Systems for Import of Allergan Cosmetics

Lupin Secures CDSCO Panel Nod for Phase IV Trial of Budesonide-Based COPD Inhaler

165 medical shops licences suspended, seven cancelled in Telangana after Abortion kits raids

Novartis Loses India Patent on Heart Failure Drug Vymada

EMA Committee approves update to Novo Nordisk Rybelsus label to reflect cardiovascular benefits

CDSCO Launches Separate Online Provision for Subsequent Importers of Medical Devices, IVDs

Aurobindo Pharma arm incorporates new wholly owned subsidiary in Malaysia